The article describes the EMEA approved indications of TNFα antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFα antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.
|Translated title of the contribution||Approved indications and other possible utilizations of anti-TNFα biologic drugs|
|Number of pages||4|
|Issue number||SUPPL. 4|
|Publication status||Published - 2005|
ASJC Scopus subject areas